Treatment of Leishmania (Leishmania) Amazonensis-Infected Mice with a Combination of a Palladacycle Complex and Heat-Killed Propionibacterium acnes Triggers Protective Cellular Immune Responses by Paladi, Carolina S. et al.
fmicb-08-00333 March 2, 2017 Time: 16:35 # 1
ORIGINAL RESEARCH
published: 06 March 2017
doi: 10.3389/fmicb.2017.00333
Edited by:
Yuji Morita,
Aichi Gakuin University, Japan
Reviewed by:
Camila I. De Oliveira,
Centro de Pesquisas Gonçalo Moniz
(FIOCRUZ), Brazil
Marcelo Santos Da Silva,
Butantan Institute, Brazil
Carlos Roberto Alves,
Oswaldo Cruz Foundation, Brazil
*Correspondence:
Clara L. Barbiéri
barbieri.clara@unifesp.br
Specialty section:
This article was submitted to
Infectious Diseases,
a section of the journal
Frontiers in Microbiology
Received: 16 November 2016
Accepted: 17 February 2017
Published: 06 March 2017
Citation:
Paladi CS, da Silva DAM, Motta PD,
Garcia DM, Teixeira D,
Longo-Maugéri IM, Katz S and
Barbiéri CL (2017) Treatment
of Leishmania (Leishmania)
Amazonensis-Infected Mice with
a Combination of a Palladacycle
Complex and Heat-Killed
Propionibacterium acnes Triggers
Protective Cellular Immune
Responses. Front. Microbiol. 8:333.
doi: 10.3389/fmicb.2017.00333
Treatment of Leishmania
(Leishmania) Amazonensis-Infected
Mice with a Combination of a
Palladacycle Complex and
Heat-Killed Propionibacterium acnes
Triggers Protective Cellular Immune
Responses
Carolina S. Paladi1, Danielle A. M. da Silva1, Priscila D. Motta1, Daniel M. Garcia2,
Daniela Teixeira1, Ieda M. Longo-Maugéri1, Simone Katz1 and Clara L. Barbiéri1*
1 Departamento de Microbiologia, Imunologia e Parasitologia, Escola Paulista de Medicina, Universidade Federal de São
Paulo, São Paulo, Brazil, 2 Departamento de Farmacologia, Escola Paulista de Medicina, Universidade Federal de São Paulo,
São Paulo, Brazil
Palladacycle complex DPPE 1.2 was previously reported to inhibit the in vitro and in vivo
infection by Leishmania (Leishmania) amazonensis. The aim of the present study was
to compare the effect of DPPE 1.2, in association with heat-killed Propionibacterium
acnes, on L. (L.) amazonensis infection in two mouse strains, BALB/c and C57BL/6,
and to evaluate the immune responses of the treated animals. Foot lesions of L. (L.)
amazonensis-infected mice were injected with DPPE 1.2 alone, or associated with P.
acnes as an adjuvant. Analysis of T-cell populations in the treated mice and in untreated
controls was performed by FACS. Detection of IFN-γ-secreting lymphocytes was carried
out by an ELISPOT assay and active TGF-β was measured by means of a double-
sandwich ELISA test. The treatment with DPPE 1.2 resulted in a significant reduction of
foot lesion sizes and parasite burdens in both mouse strains, and the lowest parasite
burden was found in mice treated with DPPE 1.2 plus P. acnes. Mice treated with
DPPE 1.2 alone displayed a significant increase of TCD4+ and TCD8+ lymphocytes
and IFN-γ secretion which were significantly higher in animals treated with DPPE 1.2
plus P. acnes. A significant reduction of active TGF-β was observed in mice treated
with DPPE 1.2 alone or associated with P. acnes. Moreover, DPPE 1.2 associated to
P. acnes was non-toxic to treated animals. The destruction of L. (L.) amazonensis by
DPPE 1.2 was followed by host inflammatory responses which were exacerbated when
the palladacycle complex was associated with P. acnes.
Keywords: cutaneous leishmaniasis, Leishmania (Leishmania) amazonensis, palladacycle complex, adjuvant,
Propionibacterium acnes
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INTRODUCTION
Parasites belonging to the Leishmania genus are etiological agents
of cutaneous, mucocutaneous, and visceral diseases in humans
and mammals. The World Health Organization estimates that
0.7 to 1.3 million of new cases of cutaneous leishmaniasis and
200,000 to 400,000 of visceral leishmaniasis occur worldwide
each year (WHO, 2015). Leishmaniasis comprises one of the
diseases included in WHO programs for control and elimination
of neglected tropical diseases (Engelman et al., 2016; Molyneux
et al., 2016). Among several Leishmania species affecting humans,
L. (L.) amazonensis is one of the causative agents of human
cutaneous leishmaniasis in the Amazon region, Brazil, associated
with both the simple and diffuse forms of the disease (Lainson
and Shaw, 1998).
Pentavalent antimonial compounds are the drugs of choice
for the treatment of these diseases, whereas amphotericin B
and pentamidine are used as a second-line therapy. However,
the use of these compounds is limited by toxicity to the host
and development of host resistance to the parasites (Goto and
Lindoso, 2010). Miltefosine showed a high efficacy for treatment
of visceral leishmaniasis in India and of cutaneous leishmaniasis
in Colombia, (Sundar et al., 2002; Soto et al., 2004) but its use
is limited by host teratogenicity and development of parasite
resistance (Croft and Coombs, 2003). Paromomycin was shown
to be effective against cutaneous and visceral leishmaniasis, but
its action depends on the causative Leishmania species (Thakur
et al., 2000). Although oral administration of sitamaquine has
shown efficacy in the treatment of visceral leishmaniasis, the drug
induces undesirable adverse effects (Jha et al., 2005). Therefore,
the development of new leishmanicidal drugs continues to be a
priority for the control of leishmaniasis and several compounds
including synthetic and natural products extracted from plants
and marine sources have exhibited different degrees of efficacy in
the treatment of experimental leishmaniasis (Sen and Chatterjee,
2011; Tempone et al., 2011; Coa et al., 2015; Ortiz et al., 2016;
Acevedo et al., 2017).
Several of the chemotherapeutic agents against leishmaniasis,
targeted to different components of the host immune system,
were endowed with immunomodulatory activity (Saha et al.,
2011). Recent insights into the host immune responses led to
identification of immunomodulators which enhance the efficacy
of antileishmanial drugs (Gupta et al., 2011; Seifert et al.,
2015). The evidence that antitumor drugs may also display
antileishmanial activity has also stimulated the screening of
these compounds in vitro and in clinical trials (Fuertes et al.,
2008; Sanderson et al., 2014). Palladacycle complexes have been
pointed out as a new class of antitumoral and antimicrobial
agents (Caires, 2007; Elgazwy et al., 2012) and the leishmanicidal
and tripanocidal effect of some of these compounds has also
been demonstrated (Fricker et al., 2008; Navarro et al., 2008;
Matsuo et al., 2010). More recently the activity of the palladacycle
complex DPPE 1.2 on L. (L.) amazonensis was described (Paladi
et al., 2012).
Previous data from our group showed the efficacy of the
heat-killed Propionibacterium acnes suspension as an adjuvant
in murine vaccination with native and recombinant antigens
against Leishmania, as well as for immunotherapy of canine
visceral leishmaniasis (Pinto et al., 2000; Ferreira et al., 2008,
2014). The adjuvant effect of P. acnes, in the past classified
as Corynebacterium parvum, was described due its capability
to enhance tumoricidal and phagocytic macrophage function
demonstrated in clinical and experimental models (Halpern
et al., 1966; Fisher et al., 1990; Salomaa et al., 1995), besides
its effects on infection resistance and antibody response (Warr
and James, 1975; Brener and Cardoso, 1976). The mechanisms
by which P. acnes modulates immune response such as increase
of proinflammatory cytokine synthesis and modulation of
Th2 to Th1 responses were demonstrated in experimental
models of tumor and allergy among others (Matsui et al.,
1997; Braga et al., 2003; Ananias et al., 2007; Squaiella-
Baptistão et al., 2015). The adjuvant effect of the killed
P. acnes was also demonstrated on vaccination studies against
Trypanosoma cruzi (Mussalem et al., 2006). All evidence on
the important immunomodulatory effects exerted by P. acnes
and our previous findings on the activity of DPPE 1.2 on L.
(L.) amazonensis led us to use P. acnes associated with this
palladacycle complex for the treatment of murine cutaneous
leishmaniasis. The murine model is very suitable for studies
of L. (L.) amazonensis infection, since several mouse strains
display different levels of susceptibility to the parasite and
mimic the various manifestations of human disease. Within
this context, we used the BALB/c strain, highly susceptible to
L. (L.) amazonensis infection that mimics the anergic form of
human diffuse cutaneous leishmaniasis and C57BL/6 that is
less susceptible to L. (L.) amazonensis infection and presents
slow development of lesions (Chang et al., 2003; Scott, 2003;
Pereira and Alves, 2008). The data of this study showed that
the high efficacy of DPPE 1.2 on L. (L.) amazonensis-infected
BALB/c and C57BL/6 mice is followed by the modulation of the
host immune responses. Furthermore, the leishmanicidal effect
of DPPE 1.2, as well as the host inflammatory responses were
exacerbated when the pallladacycle complex was associated with
P. acnes.
MATERIALS AND METHODS
Experimental Animals
Eight-week-old female Golden hamsters were obtained from
breeding stocks of Anilab Company, Paulínia (São Paulo, Brazil).
Female BALB/c and C57BL/6 mice 6 to 8 weeks old were acquired
from Universidade Federal de São Paulo (São Paulo, Brazil).
All animals were bred and housed under specific pathogen-free
conditions and fed a regular diet. All animal procedures were
carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
Brazilian National Council of Animal Experimentation1. The
protocol was approved by the Committee on the Ethics of
Animal Experiments of the Institutional Animal Care and Use
Committee at the Federal University of São Paulo (Id # CEUA
5332050514).
1http://www.cobea.org.br/
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Parasites
The L. (L.) amazonensis strain used (MHOM/BR/1973/M2269)
was kindly provided by Dr. Jeffrey J. Shaw, Instituto Evandro
Chagas, Belém, Pará, Brazil and maintained as amastigotes by
inoculation into footpads of Golden hamsters every 4 to 6 weeks
as previously described (Barbiéri et al., 1990).
Biphosphinic Palladacycle Complex
[Pd(C2, N-S(-)DMPA)(DPPE)]Cl (DPPE 1.2)
The palladacycle compound DPPE 1.2 (Paladi et al., 2012)
was obtained from N,N-dimethyl-1-phenylethylamine (DMPA),
complexed to 1,2-ethane-bis(diphenylphosphine; DPPE) ligand
and synthesized as previously described (Rodrigues et al., 2003).
Stock solutions at 1.45 mM were prepared in phosphate buffered
saline (PBS; 137 mM NaCl in 10 mM phosphate buffer, pH 7.4)
after solubilization in dimethylsulfoxide (final concentration of
0.1%).
Heat-Killed P. acnes Suspension
Propionibacterium acnes was obtained from Instituto Adolfo
Lutz, São Paulo, S.P., Brazil and cultured in anaerobic medium
(Hemobac, Probac, São Paulo, S.P., Brazil) for 3 days at 37◦C and
washed by centrifugation (Mussalem et al., 2012). The resulting
pellets were suspended in 0.9% saline and subjected to continuous
water vapor for 20 min at 120◦C. The protein concentration of the
suspension was determined by the Bradford method (Bradford,
1976).
In vivo Antileishmanial Assays
In vivo leishmanicidal activity of either DPPE 1.2 or DPPE 1.2
plus P. acnes was evaluated in female BALB/c and C57BL/6
mice 6 to 8 weeks-old infected subcutaneously at the right
hind-foot with 1 × 105 L. (L.) amazonensis amastigotes freshly
prepared as previously described. Fifteen days after infection,
the animals were randomly separated in five groups of 12 mice
each. Treated animals received in the foot lesions every other
day doses of either 60 mg/kg/day (16.8 mg [Sbv]/kg/day) of
Glucantime for 1 month (total of 1,200 mg/kg/animal–336 mg
[Sbv]/kg/animal) or doses of 320 mg/kg/day of DPPE 1.2 (total
of 6.4 mg/kg). Animals treated with DPPE 1.2 plus P. acnes
received 3 doses of 100 µg of P. acnes with an interval of 7 days
among them and every other day doses of 320 mg/kg/day of
DPPE 1.2 (total of 6.4 mg/kg). Control group received the same
number of injections of either PBS or P. acnes alone. Infection was
monitored once a week by measuring the diameter of foot lesions
with a dial caliper (Mitutoyo Corp., Japan). Parasite burden was
evaluated by limiting dilution in foot lesions of BALB/c and
C57BL/6 mice 15 days after end of the treatment, as previously
described (Lima et al., 1997). Treatment of non-infected BALB/c
and C57BL/6 mice with either DPPE 1.2 alone or associated with
P. acnes was also performed.
Assays for Toxicity
Serum concentrations of urea, creatinine, and transaminases
were determined in BALB/c and C57BL/6 mice at the end of
treatment, using sets of commercial reagents (Doles Reagentes e
Equipamentos para Laboratórios, Ltda, Brazil).
Evaluation of Immune Responses
The T lymphocyte population was analyzed by fluorescence-
activated cell sorter (FACS). The cell suspension from popliteal
and inguinal lymph nodes of all BALB/c and C57BL/6 were
pooled and counted with Trypan Blue to determine the
viability and cellular concentration. After washing with PBS,
1 × 106 lymphocytes were fixed in formalin 1% in PBS for
30 min at 4◦C, washed twice in PBS, resuspended in PBS
and incubated with monoclonal antibodies either anti-CD3
conjugated to allophycocyanin (APC), or anti-CD4 conjugated
to phycoerythrin (PE) or anti-CD8 conjugated to peridinin
chlorophyll protein (PerCP; Pharmingen) for 1 h at 4◦C, washed
twice in PBS, fixed in formalin 1% in PBS for 30 min at 4◦C,
washed twice in PBS, resuspended in PBS and gated on the basis
of forward-angle and right-angle scatter and the fluorescence
intensity was analyzed by FACS (FACSCAN – Cell Sorter
Becton–Dickinson). The absolute number of each T lymphocyte
subpopulation was determined by multiplying the total number
of cell suspension obtained from popliteal and inguinal lymph
nodes by the percentages of each subset obtained by FACS.
The enzyme-linked immunospot (ELISPOT) assay for
detection of IFN-γ-secreting lymphocytes was performed with
BD ELISPOT reagents (BD Biosciences). Briefly, the plates were
prepared by coating the wells of 96-well PVDF membrane plates
with a solution of sterile PBS containing 100 µl of the anti-mouse
IFN-γ MAb 5 µg/ml. After overnight incubation at 4◦C, the MAb
solution was removed by sterile aspiration and the plates were
washed three times with RPMI medium under sterile conditions.
Plates were blocked by incubating wells with 200 µl of RPMI
medium containing 10% (vol/vol) fetal calf serum for at least 2 h
at 37◦C. A suspension containing 5 × 105 lymphocytes isolated
from popliteal and inguinal lymph nodes from treated mice was
added to each well and cultured in 200 µl of RPMI containing
20 mM NaHCO3, 10 mM Hepes, 100 U/ml penicillin, 100 µg/ml
streptomycin, 2 mM L-glutamine, 50 µM β-mercaptoethanol,
5 mM sodium pyruvate, 100 µM of non-essential amino acids
solution and 2% normal mice serum and maintained for 72 h
in the presence of L. (L.) amazonensis amastigote extract
(corresponding to 1 × 107 amastigotes/well). The lymphocytes
were incubated for 72 h at 37◦C in an atmosphere containing
5% CO2. After incubation, cultured cells were removed from
the plates by washing two times with distilled water and three
times with PBS-Tween. Each well received 100 µl of biotinylated
anti-mouse IFN-γ diluted in PBS-Tween to a final concentration
of 2 µg/ml. Plates were incubated for 2 h at room temperature,
unbound antibodies were removed by washing the plates at least
six times with PBS-Tween and 250 µg/ml of peroxidase-labeled
streptavidin (HRP) was added. Plates were incubated for 1 h
at room temperature and then washed three to five times with
PBS-Tween and three times with PBS. The reactions on the
plates were developed by adding 100 µl of freshly prepared
AEC substrate solution (0.33 mg/ml 3-amino-9-ethylcarbazole,
3% N,N-dimethylformamide, 0,015% hydrogen peroxide in
0.1 M sodium acetate buffer, pH 5,0). After incubation at room
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temperature for 15 min, the reaction was stopped by discarding
the substrate solution and rinsing the plates with water. Plates
were dried at room temperature, and spots were counted with
the aid of a stereomicroscope (Nikon).
Detection of active TGF-β was carried out in the supernatants
of foot lesions from treated BALB/c and C57BL/6 mice.
The animals were euthanized, and after homogenization of
excised lesions in PBS, supernatants were collected, cleared by
centrifugation, and assayed for TGF-β by using a double-
sandwich ELISA assay according to the manufacturer
instructions (eBioscience, Inc., San Diego, CA, USA).
Supernatant concentrations higher than the minimal values
obtained from the TGF-β standard were considered to be
positive.
Statistical Analysis
One-way ANOVA and Student’s t-test were used to determine
the significant differences between groups by use of GraphPad
Prism (version 5.0) and P values smaller than 0.05 (P< 0.05) were
considered significant.
RESULTS
Association with the Adjuvant P. acnes
Increased the Leishmanicidal Effect of
DPPE 1.2 in BALB/c and C57BL/6 Mice
Infected with L. (L.) amazonensis
Previous data showed that the treatment of L. (L.) amazonensis-
infected BALB/c mice with DPPE 1.2 was followed by increase
of TCD4+ and TCD8+ lymphocyte populations (data not
shown). These results and previous evidence that P. acnes exerts
important immunomodulatory effects led us to use P. acnes as
an adjuvant for the treatment with DPPE 1.2 in order to increase
both the immune responses and the leishmanicidal activity of this
palladacycle complex in BALB/c mice. In addition, a strain less
susceptible to L. (L.) amazonensis infection, C57BL/6, was also
used for the treatment with DPPE 1.2 plus P. acnes. Furthermore,
as a positive control, both mouse strains infected with L. (L.)
amazonensis were treated with Glucantime, the drug of choice for
the treatment of leishmaniasis.
Figures 1A,C show that starting from 28 days of treatment the
animals which received either DPPE 1.2 or DPPE 1.2 + P. acnes
showed a significant decrease of foot lesion size compared
to controls. Animals treated with Glucantime also exhibited
significantly smaller foot lesions compared to untreated control,
as well as to animals treated with either DPPE 1.2 or DPPE 1.2
+ P. acnes. Furthermore, C57BL/6 mice treated with DPPE 1.2
+ P. acnes showed a significant reduction of foot lesion size
compared to that observed in animals treated with DPPE 1.2
alone.
Parasite loads are shown in Tables 1, 2 and Figures 1B,D.
As can be observed, BALB/c and C57BL/6 mice treated
with either DPPE 1.2, DPPE 1.2 + P. acnes or Glucantime
displayed a significant reduction of parasite load compared to
untreated animals. Among the three groups, parasite loads were
significantly lower in both strains treated with DPPE 1.2 plus
P. acnes compared to those estimated in animals treated with
DPPE 1.2 alone. Furthermore, the parasite load of C57BL/6
mice treated with DPPE 1.2 plus P. acnes was also lower than
that exhibited by animals treated with Glucantime (Figure 1D).
Figure 2 illustrates the macroscopic features of foot lesions in
untreated mice or in mice treated with either DPPE 1.2 alone or
associated with P. acnes or Glucantime 15 days after the end of
treatment.
The hepato and nephrotoxicity of DPPE 1.2, DPPE 1.2
plus P. acnes and Glucantime was evaluated by determination
of serum levels of transaminases, urea, and creatinine from
treated mice. No statistically significant alterations were detected
between groups (Figure 3).
Increase of TCD4+ and CD8+
Lymphocytes in L. (L.)
amazonensis-Infected BALB/c and
C57BL/6 Mice after Treatment with DPPE
1.2 Associated with P. acnes
The analysis of T lymphocyte expression by FACS was performed
in the interval between the second and third administration of
P. acnes in both mouse strains and until this time the animals
had received either 1.92 mg/kg of DPPE 1.2 alone or associated
to 200 µg of P. acnes or 360 mg/kg of Glucantime. There was
a significant increase of TCD4+ and TCD8+ lymphocytes in
BALB/c and C57BL/6 mice treated either with DPPE 1.2 or
DPPE 1.2 + P. acnes compared to control groups (Figure 4 and
Supplementary Figure 1). Both strains treated with DPPE 1.2
plus P. acnes exhibited significantly higher number of TCD4+
and TCD8+ compared to those treated with DPPE 1.2 alone. No
statistical differences in T lymphocyte expression was observed
in animals treated with Glucantime compared to controls that
received either PBS or PBS + P. acnes. The number of TCD4+
and TCD8+ lymphocytes was not significantly different between
BALB/c and C57BL/6 mice treated with either DPPE 1.2 alone or
associated to P. acnes.
Non-infected BALB/c and C57BL/6 mice treated with
1.92 mg/kg of DPPE 1.2 alone or associated to 200 µg of P. acnes
did not show increase of TCD4+ and TCD8+ lymphocytes
(Supplementary Figure 2).
Treatment with DPPE 1.2 Associated
with P. acnes Resulted in Increase of
IFN-γ and Reduction of TGF-β Secretion
in BALB/c and C57BL/6 Mice Infected
with L. (L.) amazonensis
At the same period of treatment lymphocytes secreting IFN-γ and
secretion of TGF-β from treated mice were evaluated. Figure 5
shows that higher frequency of IFN-γ-secreting lymphocytes
was found in BALB/c and C57BL/6 mice treated with either
DPPE 1.2 alone or associated with P. acnes compared to those
that received PBS. The increase of IFN-γ-secreting lymphocytes
was significantly higher in animals treated with DPPE 1.2 plus
P. acnes compared to those treated with DPPE 1.2 alone, while
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FIGURE 1 | Effect of DPPE 1.2 alone or associated with P. acnes on BALB/c (A,B) and C57BL/6 mice (C,D) infected with L. (L.) amazonensis. (A,C)
Development of foot lesions in treated mice. The treatment was started 15 days after infection and continued for 7 weeks. Data points represent the average
measurements for five groups of 12 mice each. (B,D) Parasite load in foot lesions evaluated by number of parasites recovered by limiting dilution from treated L. (L.)
amazonensis-infected mice. Parasites were quantified 15 days after interruption of treatment. Data are representative of three independent experiments. ∗P < 0.05
compared to untreated animals; •P < 0.01 compared to animals treated with DPPE 1.2 alone; #P < 0.01 compared to animals treated with Glucantime.
TABLE 1 | Parasite load of L. (L.) amazonensis-infected BALB/c mice
15 days after interruption of treatment with DPPE 1.2 alone or associated
with P. acnes.
Group Parasite load
PBS 33.5 × 1011
PBS + P. acnes 46 × 1011
DPPE 1.2 1.92 × 107
DPPE 1.2 + P. acnes 7.2 × 106
Glucantime 1.03 × 107
no difference in IFN-γ production was observed between the two
mouse strains.
Data on TGF-β dosages are shown in Figure 6. High levels
of active TGF-β were detected in the foot lesions from mice that
received either PBS, P. acnes or Glucantime, in contrast to those
treated with either DPPE 1.2 alone or associated with P. acnes that
displayed a significant reduction of TGF-β production. Although
both mouse strains treated with DPPE 1.2 plus P. acnes displayed
lower concentrations of TGF-β than those treated with DPPE 1.2
alone, this difference was not significant. It was also observed
that the concentration of active TGF-β in lesions of BALB/c mice
TABLE 2 | Parasite load of L. (L.) amazonensis-infected C57BL/6 mice
15 days after interruption of treatment with DPPE 1.2 alone or associated
with P. acnes.
Group Parasite load
PBS 18.26 × 1011
PBS + P. acnes 20.55 × 1011
DPPE 1.2 4.66 × 106
DPPE 1.2 + P. acnes 6.56 × 103
Glucantime 3.74 × 104
was about twofold lower than that found in C57BL/6. However,
the reduction of TGF-β in treated animals was not significantly
different between the two strains.
DISCUSSION
The present study compared the effect of DPPE 1.2 associated
with P. acnes on L. (L.) amazonensis infection in BALB/c and
C57BL/6 mice. All animals from both strains treated with DPPE
1.2 displayed a significant reduction of parasite load and this
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FIGURE 2 | Macroscopic evaluation of lesions in controls and treated mice. L. (L.) amazonensis-infected BALB/c (A) and C57BL/6 (B) mice treated with
either DPPE 1.2 alone, DPPE 1.2 associated with P. acnes or Glucantime 15 days after the end of treatment.
FIGURE 3 | Evaluation of toxicity in L. (L.) amazonensis-infected BALB/c and C57BL/6 mice after treatment with DPPE 1.2 alone or associated with
P. acnes. Serum concentrations of creatinine (A), urea (B) and transaminases (C) in L. (L.) amazonensis-infected mice 15 days after the end of treatment with either
DPPE 1.2, DPPE 1.2 plus P. acnes or Glucantime. The reference values are: creatinine: 0.3–1.0 mg/dl; urea: 34–58 mg/dl; transaminases: ALT: 53–202 UI/L, AST:
28–107 UI/L.
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FIGURE 4 | Absolute number of T lymphocyte populations in treated mice. L. (L.) amazonensis-infected BALB/c (A) and C57BL/6 (B) mice were treated with
either DPPE 1.2 alone or associated with P. acnes or Glucantime. Lymphocytes were isolated from popliteal and inguinal lymph nodes, stained with monoclonal
antibodies anti-CD3, anti-CD4 and anti-CD8 and analyzed by FACS. ∗P < 0.01 compared to control that received PBS; •P < 0.05 compared to group that received
DPPE 1.2 alone.
FIGURE 5 | Frequency of IFN-γ-secreting lymphocytes in treated mice. BALB/c (A) and C57BL/6 (B) mice infected with L. (L.) amazonensis were treated with
either DPPE 1.2 alone or associated with P. acnes or Glucantime. Lymphocytes were isolated from popliteal and inguinal lymph nodes and after 96 h of stimulation
in vitro with extract of L. (L.) amazonensis amastigotes were detected by ELISPOT technique. ∗P < 0.05 compared to control that received PBS; •P < 0.05
compared to group that received DPPE 1.2 alone.
reduction was significantly higher in mice treated with DPPE 1.2
plus P. acnes. The treatment with DPPE 1.2 resulted in a twofold
higher reduction of parasite load in C57BL/6 mice compared
to that observed in BALB/c strain, while this difference was of
600-fold between the two strains treated with DPPE 1.2 plus
P. acnes. These results reflect the different susceptibility to L.
(L.) amazonensis of these strains, since BALB/c mice develop an
anergic form of diffuse cutaneous leishmaniasis characterized by
metastasizing and non-self-healing foot lesions harboring a high
number of amastigotes (Andrade et al., 1984). On the other hand,
infection by L. (L.) amazonensis in the C57BL/6 strain generates
lesions which tend to chronicity (Calabrese and Costa, 1992).
Therefore, the higher difference observed between the two mouse
strains treated with DPPE 1.2 plus P. acnes probably is due to
intrinsic characteristics of the C57BL/6 strain that resulted in
a more responsiveness to the stimulus induced by the adjuvant
and in a higher protection in these animals. However, despite of
the significant increase of CD4+ and CD8+ T lymphocytes in
animals treated with DPPE 1.2 plus P. acnes compared to that
observed in mice treated with DPPE 1.2 alone, no differences
were observed in the number of these T lymphocyte populations
between the two strains after treatment with DPPE 1.2 plus
P. acnes.
The higher frequency of lymphocytes producing IFN-γ and
the increase of T lymphocytes in mice treated with either DPPE
1.2 or DPPE 1.2 plus P. acnes indicate the involvement of CD8+
and CD4+ Th1 cells in the production of this lymphokine in these
groups. The participation of TCD4+ Th1 lymphocytes producing
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FIGURE 6 | Evaluation of TGF-β in treated mice. Levels of active TGF-β were determined by ELISA assay in supernatants of foot lesions from L. (L.) amazonensis
infected BALB/c (A) and C57BL/6 mice (B) treated with either DPPE 1.2 alone or associated with P. acnes or Glucantime. ∗P < 0.01 compared to control groups.
IFN-γ has been demonstrated in mice protected against L.
(L.) amazonensis infection (Coelho et al., 2003; Pinto et al.,
2004). Furthermore, the involvement of CD8+ T lymphocytes
producing perforin and IFN-γ was also demonstrated in BALB/c
mice immunized with Leishmania antigen and protected against
a challenge with L. (L.) amazonensis (Colmenares et al., 2003).
It is also important to emphasize that the significant increase of
CD4+ and CD8+ T lymphocytes, as well as the IFN-γ production
in mice treated with DPPE 1.2 plus P. acnes compared to those
treated with DPPE 1.2 alone are in accordance with previous
data that showed that treatment with P. acnes elicits a type-1
(Th1) immune response involving IL-12 and IL-18 that induces
IFN-γ release (Matsui et al., 1997). Administration of killed
P. acnes as an adjuvant increased the resistance to infection by
T. cruzi (Mussalem et al., 2006) and in leishmaniasis this adjuvant
was used in murine vaccination with native and recombinant
antigens resulting in protective immunity mediated by CD4+
Th1 lymphocytes (Pinto et al., 2000; Ferreira et al., 2008). More
recently, P. acnes was also used in association to a recombinant
cysteine proteinase from L. (L.) infantum chagasi for treatment of
canine visceral leishmaniasis (Ferreira et al., 2014).
Data on IFN-γ production suggest the involvement of this
cytokine in parasite destruction of mice treated with either DPPE
1.2 or DPPE 1.2 plus P. acnes. However, it is possible to assign
to cytotoxic CD8+ lymphocytes a more relevant role in parasite
load decrease in treated mice as recent data showed that the L. (L.)
amazonensis strain used in the present study is unresponsive to
nitric oxide secreted by macrophages activated by IFN-γ (Carmo
et al., 2010). This hypothesis is supported by previous data
which showed an increase of CD8+ expression parallel to their
cytotoxic activity on L. (L.) amazonensis-infected macrophages
from BALB/c mice immunized with a recombinant cysteine
proteinase from L. (L.) amazonensis and partially protected
against homologous infection (Fedeli et al., 2010). Furthermore,
the relevant role of cytotoxic TCD8+ lymphocytes in L. (L.)
amazonensis infection was demonstrated by other authors (Alves
et al., 2004; Pereira and Alves, 2008; Pereira et al., 2011; Souza-
Silva et al., 2014).
TGF-β was demonstrated to exacerbate infection by cutaneous
and visceralizing Leishmania species (Barral-Netto et al., 1992;
Pinheiro et al., 2005). The present data corroborate these results
since low levels of TGF-β were detected in foot lesions from
mice treated with either DPPE 1.2 or DPPE 1.2 plus P. acnes
with a concomitant reduction of parasite load, increase of CD4+
and CD8+ T lymphocytes and significant secretion of IFN-
γ. Secretion of IFN-γ was not different between BALB/c and
C57BL/6 mice treated with either DPPE 1.2 or DPPE 1.2 plus
P. acnes, while the production of TGF-β was about twofold higher
in C57BL/6 strain. However, the reduction of active TGF-β levels
in animals treated with either DPPE 1.2 or DPPE 1.2 plus P. acnes
was similar between the two strains.
The treatment of L. (L.) amazonensis-infected BALB/c mice
with either DPPE 1.2 alone or Glucantime resulted in a similar
reduction of parasite load. On the other hand, in C57BL/6 strain
the treatment with Glucantime resulted in a significantly higher
reduction of parasite load than that observed in animals treated
with DPPE 1.2 alone, whereas this reduction was lower when
compared to that evaluated in mice treated with DPPE 1.2
plus P. acnes. These findings strengthen that C57BL/6 is more
responsive to the stimulus induced by P. acnes, as discussed
above. It is worth noting that although the reduction of parasite
load in BALB/c mice treated with DPPE 1.2 was similar to that
obtained with Glucantime, this antimonial compound was used
in 200-fold higher concentration. The leishmanicidal mechanism
of Glucantime has not been clearly elucidated, but several
reports show that direct and indirect mechanisms are involved
in Leishmania destruction by this antimonial and the host
immune system has also been implicated in its leishmanicidal
activity (Muniz-Junqueira and de Paula-Coelho, 2008). Our
findings showed that in both mouse strains the treatment with
Glucantime did not increase the number of CD4+ T and CD8+
T lymphocytes. Moreover, IFN-γ and TGF-β secretion in foot
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lesions of animals treated with Glucantime was not different than
that observed in non-treated controls, indicating that in both
mouse strains the leishmanicidal activity of Glucantime is not
mediated by activation of cellular immune response against L. (L.)
amazonensis.
Interestingly, our data also showed that is crucial the presence
of parasites for the immunomodulatory effect of DPPE 1.2, since
the administration of this palladacycle complex to non-infected
mice did not result in activation of the immune system. This is
certainly related to the leishmanicidal mechanism of DPPE 1.2
that needs to be further explored.
CONCLUSION
The present study strengthened our previous results on activity
of DPPE 1.2 on L. (L.) amazonensis and showed that in vivo
treatment with this palladacycle complex led to the stimulation of
cellular immune responses mediated by both CD4+ and CD8+ T
lymphocytes in treated mice. Furthermore, a significantly higher
reduction of foot lesion size and parasite burden followed by
a higher increase of CD4+ and CD8+ T lymphocytes could be
observed in both strains treated with DPPE 1.2 plus P. acnes
compared to that found in animals treated with DPPE 1.2 alone.
These findings open perspectives to explore the potential of DPPE
1.2 associated with P. acnes as an additional option for the
chemotherapy of leishmaniasis.
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